Hadassah

ALS Stem Cell Trial Yielding “Impressively Positive” Findings

Thursday, Jan 2 2014

Commenting on the Phase IIa trial of NurOwn™--BrainStorm Cell Therapeutics' stem cell therapy for amyotrophic lateral sclerosis (ALS)--which is being conducted at the Hadassah Medical Organization, Prof. Dimitrios Karussis, principal investigator, reports that the safety data are "impressively positive" and that the "initial indications of clinical efficacy" are cause for optimism regarding the management of ALS and the future of cell therapies for neurodegenerative diseases in general.

Prof. Karussis, Neurologist and Director of the Multiple Sclerosis Center at Hadassah, presented some of his preliminary findings from this ongoing dose-escalating trial at the 24th International Symposium on ALS/MND in Milan, Italy. MND, Motor Neuron Disease, is the name given to a group of diseases in which the nerve cells (neurons) that control muscles undergo degeneration and die.

According to Prof. Karussis, although the final data are not yet available for publication because the trial is still ongoing, researchers have met with only minimal and transient adverse effects, even though the patients in the study were given the treatment both intrathecally (into the cerebrospinal fluid by injection into the subarachnoid space of the spinal cord) and intramuscularly, with up to double the dose of the stem cells given in the Phase I trial.

At the conclusion of the clinical trial, BrainStorm will release the complete set of data and corresponding analyses.

Related Stories

alt_text

Wednesday, Apr 8 2020

Hadassah to Launch Clinical Trials of a Serum to Fight COVID-19

For the first time in Israel, Hadassah Hospital Ein Kerem is collecting plasma from recovered COVID-19 patients...

READ MORE ›
alt_text

Tuesday, Apr 7 2020

Virtual Community Gathering: Israel's Response to the Coronavirus

Israel's experts talk about the Coronavirus, how Israel responded and "best practices" developed via a Zoom panel discussion which included Hadassah Prof. Ran Nir-Paz, Infectious DIsease Physician.

READ MORE ›
alt_text

Tuesday, Apr 7 2020

Hadassah to Initiate Trials of Japanese Drug to Fight COVID-19 READ MORE ›
alt_text

Monday, Apr 6 2020

Hadassah Cardiologist: Don’t Let Fear of COVID-19 Keep You From Urgent Care

The advice to "stay home" should not be heeded if you have chest pains or other signs of a heart attack, warns Hadassah...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More